Bausch Health Companies Inc. Fair Value of Long-Term Debt
Bausch Health Companies Inc. (BHC) had Fair Value of Long-Term Debt of $26.30 billion as of 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:LongTermDebtFairValue · last filed 2017-03-01
- 2016-12-31: Long-term Debt, Fair Value $26.30B.
- 2016-09-30: Long-term Debt, Fair Value $28.85B.
- 2016-06-30: Long-term Debt, Fair Value $27.63B.
- 2016-03-31: Long-term Debt, Fair Value $27.72B.
| Period end | Long-term Debt, Fair Value | Long-term Debt, Fair Value as first filed |
|---|---|---|
| 2016-12-31 | $26.30B 10-K · filed 2017-03-01 | |
| 2016-09-30 | $28.85B 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $27.63B 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $27.72B 10-Q · filed 2016-06-07 | |
| 2015-12-31 | $29.60B 10-K · filed 2017-03-01 | $29.60B 10-K · filed 2016-04-29 |
| 2015-09-30 | $30.50B 10-Q · filed 2015-10-26 | |
| 2015-06-30 | $31.85B 10-Q · filed 2015-07-28 | |
| 2015-03-31 | $26.93B 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $15.78B 10-K · filed 2016-04-29 | $15.80B 10-K · filed 2015-02-25 |
| 2014-09-30 | $16.80B 10-Q · filed 2014-10-24 | |
| 2014-06-30 | $18.20B 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $18.40B 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $18.40B 10-K · filed 2015-02-25 | $18.38B 10-K · filed 2014-02-28 |
| 2013-09-30 | -$18.30B 10-Q · filed 2013-11-01 | |
| 2013-03-31 | $11.20B 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $11.69B 10-K · filed 2014-02-28 | $11.70B 10-K · filed 2013-02-28 |
| 2012-09-30 | $8.10B 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $7.80B 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $7.10B 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $6.70B 10-K · filed 2013-02-28 | |
| 2010-12-31 | $4.20B 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |